Business
Press Release Apr 08 2021
Cadila Healthcare Limited has informed the Exchange regarding a press release dated April 08, 2021, titled "Zydus Cadila announces USFDA approval for First Generic for Ibrutinib Capsules, 70 mg and gets eligibility for 180-day exclusivity".
About this update from Zydus Lifesciences Limited
[{"type":"text","content":" Cadila Healthcare Limited has informed the Exchange regarding a press release dated April 08, 2021, titled \"Zydus Cadila announces USFDA approval for First Generic for Ibrutinib Capsules, 70 mg and gets eligibility for 180-day exclusivity\". View Attachment","length":394,"tagName":"div"}]